Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer.

by Cheryl A London, Misty D Bear, Jennifer McCleese, Kevin P Foley, Reji Paalangara, Takayo Inoue, Weiwen Ying, James Barsoum
Published 2011-01-01

Phase I/II evaluation of RV1001, a novel PI3Kδ inhibitor, in spontaneous canine lymphoma.

by Heather L Gardner, Sarah B Rippy, Misty D Bear, Kim L Cronin, Heather Heeb, Holly Burr, Claire M Cannon, Kumar V Penmetsa, Srikant Viswanadha, Swaroop Vakkalanka, Cheryl A London
Published 2018-01-01

Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.

by Cheryl A London, Luis Feo Bernabe, Sandra Barnard, William C Kisseberth, Antonella Borgatti, Mike Henson, Heather Wilson, Kiersten Jensen, Daisuke Ito, Jaime F Modiano, Misty D Bear, Michael L Pennell, Jean-Richard Saint-Martin, Dilara McCauley, Michael Kauffman, Sharon Shacham
Published 2014-01-01